New approach to management of chronic vascular rejection with prostacyclin analogue after kidney transplantation.
D001550:Benzamidines; D001792:Blood Platelets / Q000502:physiology; D003505:Cyclodextrins; D011464:Epoprostenol / Q000031:analogs & derivatives; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D006084:Graft Rejection; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000098:blood supply*; D016030:Kidney Transplantation; D014652:Vascular Diseases / Q000188:drug therapy* / Q000276:immunology; D047391:alpha-Cyclodextrins
D001550:Benzamidines; D003505:Cyclodextrins; D004952:Esters; D006146:Guanidines; D047391:alpha-Cyclodextrins; C034532:camostat; C051518:OP 41483-alpha-cyclodextrin; D016670:Gabexate; D011464:Epoprostenol; C032855:nafamostat